GlassScriptPhysician profile
Ekta Purohit
NPI 1669145959
$2,525.26
in general payments reported to CMS, 2019-2025
12 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $1,986 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340 · Travel and Lodging: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.99 |
| Travel and Lodging | $1,185.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals As | $1,583.83 | 2024 | Adstiladrin |
| Sumitomo Pharma America, INC. | $286.62 | 2023-2025 | Gemtesa |
| Urogen Pharma, INC. | $180.86 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.01 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $83.44 | 2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $70.02 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $49.46 | 2024 | Keytruda |
| Tolmar, INC. | $43.34 | 2024 | |
| Immunitybio, INC. | $32.12 | 2024-2025 | |
| Photocure INC | $23.98 | 2023 | Cysview |
| Blue Earth Diagnostics | $19.29 | 2024 | |
| 180 Medical, INC. | $15.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekta Purohit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.